Michiel Simon Jan Buijze
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michiel Simon Jan Buijze has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Rinze Frederik Neuteboom
Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands
4 shared publications - Arlette Laurien Bruijstens
Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
2 shared publications Sandy Molenaar
Division of Pediatric Neurology, Department of Neurology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
2 shared publications- Sandy Molenaar
Department of Neurology, Erasmus University Medical Centre, Rotterdam, The Netherlands
2 shared publications Arlette L. Bruijstens
Erasmus MC University Medical Center Rotterdam, Department of Neurology, Rotterdam, The Netherlands
1 shared publication- Beatrijs Wokke
Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 6 August 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (11) , 1168-1181
Frequent early cognitive impairment in both pediatric MS and MOGAD
Background: Studies on early cognitive impairment (CI) in pediatric multiple sclerosis (MS) are heterogeneous and data on pediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are scarce. Objectives: To evaluate early cognitive dysfunction in both diseases and delineate disease-specific neurocognitive profiles. Methods: A cross-sectional study of children with MS and MOGAD assessed neurocognition within 2 years after disease onset using a comprehensive test battery. Test results were converted to Z -scores. CI was defined as Z -scores below −1.5 in ⩾2 domains. Children were compared by CI status and domain deficits quantified with composite Z -scores. Results: Sixty-seven participants were analyzed (MS n = 36, MOGAD n = 31). Despite normal full-scale intelligence quotient, 47% of MS children and 43% of MOGAD children (acute disseminated encephalomyelitis excluded) met criteria for CI. Domain-specific impairments were prominent in complex attention, with significantly reduced composite Z -scores (MS: −1.24, p < 0.001; MOGAD: −1.12, p = 0.019). MS children additionally showed lower scores on tasks of visuospatial processing and visual memory. Only fatigue was significantly associated with the presence of CI (PedsQL fatigue Z -score: −2.61 vs −0.75, p = 0.005). Conclusion: In both pediatric MS and MOGAD, early CI is prevalent with difficulties in complex attention. Visuospatial cognition appears to be an additional vulnerable area for children with MS.
- 6 August 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (11) , 1168-1181
Open AccessFrequent early cognitive impairment in both pediatric MS and MOGAD
Background: Studies on early cognitive impairment (CI) in pediatric multiple sclerosis (MS) are heterogeneous and data on pediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are scarce. Objectives: To evaluate early cognitive dysfunction in both diseases and delineate disease-specific neurocognitive profiles. Methods: A cross-sectional study of children with MS and MOGAD assessed neurocognition within 2 years after disease onset using a comprehensive test battery. Test results were converted to Z -scores. CI was defined as Z -scores below −1.5 in ⩾2 domains. Children were compared by CI status and domain deficits quantified with composite Z -scores. Results: Sixty-seven participants were analyzed (MS n = 36, MOGAD n = 31). Despite normal full-scale intelligence quotient, 47% of MS children and 43% of MOGAD children (acute disseminated encephalomyelitis excluded) met criteria for CI. Domain-specific impairments were prominent in complex attention, with significantly reduced composite Z -scores (MS: −1.24, p < 0.001; MOGAD: −1.12, p = 0.019). MS children additionally showed lower scores on tasks of visuospatial processing and visual memory. Only fatigue was significantly associated with the presence of CI (PedsQL fatigue Z -score: −2.61 vs −0.75, p = 0.005). Conclusion: In both pediatric MS and MOGAD, early CI is prevalent with difficulties in complex attention. Visuospatial cognition appears to be an additional vulnerable area for children with MS.
- Open Access
- 3 August 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (8) , e70723
Update on the Incidence of Paediatric Multiple Sclerosis, Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease, Aquaporin‐4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder, and Other Acquired Demyelinating Syndromes in the Netherlands, 2017–2025, Including the COVID ‐19 Pandemic
Background: Acquired demyelinating syndromes (ADS) in children include multiple sclerosis (MS), myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), aquaporin 4 antibody‐positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD), and other seronegative disorders. We previously reported an increased incidence of overall paediatric ADS and MS between 2007 to 2010 and 2011–2016 (from 0.66 to 0.80 and 0.15 to 0.26 per 100,000 person‐years, respectively). Environmental factors, including viral exposure, may influence these rates. Comparing a recent period that includes the COVID‐19 pandemic provides an opportunity to study temporal patterns. Methods: Children < 18 years with a first demyelinating event between January 2017 and June 2025 were prospectively included in the nationwide PROUDkids 2.0 study or referred to the Dutch Paediatric MS Centre. Diagnoses followed international criteria, and incidence rates were calculated using national population data. Results: Among 257 included children, 111 (43%) had MS, 93 (36%) MOGAD, 5 (2%) AQP4+ NMOSD, and 48 (19%) seronegative ADS. Overall ADS incidence was 0.91 per 100,000 person‐years, with MS 0.40, MOGAD 0.33, AQP4+ NMOSD 0.02, and seronegative ADS 0.16 per 100,000 person‐years. Compared with 2011–2016 (0.26 per 100,000), MS incidence increased, whereas other ADS rates remained stable. MS incidence declined after COVID‐19 restrictions, particularly among adolescents, while MOGAD incidence rose modestly in younger children during the COVID restrictions. Conclusions: Paediatric MS incidence continues to rise in the Netherlands, whereas the incidence of other ADS remains stable. Temporal variations in the incidence of MS and MOGAD during and after the COVID‐19 pandemic may reflect the influence of viral exposure in their pathogenesis.
- 3 August 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (8) , e70723
Open AccessUpdate on the Incidence of Paediatric Multiple Sclerosis, Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease, Aquaporin‐4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder, and Other Acquired Demyelinating Syndromes in the Netherlands, 2017–2025, Including the COVID ‐19 Pandemic
Background: Acquired demyelinating syndromes (ADS) in children include multiple sclerosis (MS), myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), aquaporin 4 antibody‐positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD), and other seronegative disorders. We previously reported an increased incidence of overall paediatric ADS and MS between 2007 to 2010 and 2011–2016 (from 0.66 to 0.80 and 0.15 to 0.26 per 100,000 person‐years, respectively). Environmental factors, including viral exposure, may influence these rates. Comparing a recent period that includes the COVID‐19 pandemic provides an opportunity to study temporal patterns. Methods: Children < 18 years with a first demyelinating event between January 2017 and June 2025 were prospectively included in the nationwide PROUDkids 2.0 study or referred to the Dutch Paediatric MS Centre. Diagnoses followed international criteria, and incidence rates were calculated using national population data. Results: Among 257 included children, 111 (43%) had MS, 93 (36%) MOGAD, 5 (2%) AQP4+ NMOSD, and 48 (19%) seronegative ADS. Overall ADS incidence was 0.91 per 100,000 person‐years, with MS 0.40, MOGAD 0.33, AQP4+ NMOSD 0.02, and seronegative ADS 0.16 per 100,000 person‐years. Compared with 2011–2016 (0.26 per 100,000), MS incidence increased, whereas other ADS rates remained stable. MS incidence declined after COVID‐19 restrictions, particularly among adolescents, while MOGAD incidence rose modestly in younger children during the COVID restrictions. Conclusions: Paediatric MS incidence continues to rise in the Netherlands, whereas the incidence of other ADS remains stable. Temporal variations in the incidence of MS and MOGAD during and after the COVID‐19 pandemic may reflect the influence of viral exposure in their pathogenesis.
- Open Access
- 17 April 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 111, 107206
A systematic review of the clinical utility of retinal optical coherence tomography in childhood acquired demyelinating syndromes
- 17 April 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 111, 107206
Open AccessA systematic review of the clinical utility of retinal optical coherence tomography in childhood acquired demyelinating syndromes
- Open Access
- 29 March 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 110, 107167
Optical coherence tomography intereye difference metrics to detect optic nerve lesions in children with inflammatory demyelinating disease
- 29 March 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 110, 107167
Open AccessOptical coherence tomography intereye difference metrics to detect optic nerve lesions in children with inflammatory demyelinating disease
- Open Access
- 18 March 2025
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 96 (10) , 975-980
Strong association with remote EBV infection in children with MS as opposed to other acquired demyelinating disorders
Background The link between multiple sclerosis (MS) and Epstein-Barr virus (EBV) is well established in adults but less clear in paediatric cases. In addition, the role of EBV and other viral infections in acquired demyelinating syndromes (ADS), including paediatric MS and myelin-oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), remains unknown. This study explores viral infections in children with MS, MOGAD and other ADS. Methods Serum samples from paediatric patients in a Dutch multicentre ADS cohort were tested for seroprevalence of EBV, cytomegalovirus (CMV) and human herpesvirus 6 (HHV-6) using immunoassays. Results 31 children with MS, 26 with MOGAD and 15 with other ADS were included. Nearly all had prior HHV-6 infection (MS 87%, MOGAD 88% and ADS 93%). All children with MS had prior EBV exposure, compared with 50% in MOGAD and 67% in other ADS (p=0.001). EBV nuclear antigen 1 (EBNA-1) and viral capsid antigen antibody levels were particularly high in the MS group. CMV seroprevalence was lower in MS (35%) than in MOGAD (58%, p=0.13), despite older age at onset (16.0 vs 10.5 years). In children with MS, no significant correlations were found between EBNA-1 levels and clinical measures like annualised relapse rate, Expanded Disability Status Scale or the presence of black holes on MRI at baseline. Conclusions All children with MS show evidence of remote EBV infection, unlike MOGAD and other ADS. EBNA-1 levels are notably high in children with MS. Remote CMV infection appears more common in MOGAD. There are no associations between serology and clinical parameters.
- 18 March 2025
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 96 (10) , 975-980
Open AccessStrong association with remote EBV infection in children with MS as opposed to other acquired demyelinating disorders
Background The link between multiple sclerosis (MS) and Epstein-Barr virus (EBV) is well established in adults but less clear in paediatric cases. In addition, the role of EBV and other viral infections in acquired demyelinating syndromes (ADS), including paediatric MS and myelin-oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), remains unknown. This study explores viral infections in children with MS, MOGAD and other ADS. Methods Serum samples from paediatric patients in a Dutch multicentre ADS cohort were tested for seroprevalence of EBV, cytomegalovirus (CMV) and human herpesvirus 6 (HHV-6) using immunoassays. Results 31 children with MS, 26 with MOGAD and 15 with other ADS were included. Nearly all had prior HHV-6 infection (MS 87%, MOGAD 88% and ADS 93%). All children with MS had prior EBV exposure, compared with 50% in MOGAD and 67% in other ADS (p=0.001). EBV nuclear antigen 1 (EBNA-1) and viral capsid antigen antibody levels were particularly high in the MS group. CMV seroprevalence was lower in MS (35%) than in MOGAD (58%, p=0.13), despite older age at onset (16.0 vs 10.5 years). In children with MS, no significant correlations were found between EBNA-1 levels and clinical measures like annualised relapse rate, Expanded Disability Status Scale or the presence of black holes on MRI at baseline. Conclusions All children with MS show evidence of remote EBV infection, unlike MOGAD and other ADS. EBNA-1 levels are notably high in children with MS. Remote CMV infection appears more common in MOGAD. There are no associations between serology and clinical parameters.
- Open Access
- 13 April 2022
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 38, 66-72
Early MRI diagnosis of Sturge Weber Syndrome type 1 in infants
- 13 April 2022
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 38, 66-72
Open AccessEarly MRI diagnosis of Sturge Weber Syndrome type 1 in infants
- Open Access
- 1 November 2020
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 20 (11) , e832-e835
Ixazomib Treatment of IgA Multiple Myeloma With Hyperviscosity Syndrome
- 1 November 2020
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 20 (11) , e832-e835
Open AccessIxazomib Treatment of IgA Multiple Myeloma With Hyperviscosity Syndrome